Johnson & Johnson and partners announced that the Imbokodo study, a large-scale HIV vaccine proof-of-concept trial also known as HVTN 705/HPX2008, did not significantly reduce the overall risk of HIV acquisition among over 2,600 women in five sub-Saharan African countries.
On September 9, AVAC held a global webinar to discuss this development and the implications for the HIV vaccine field. Watch the recording.